JP2017019776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017019776A5 JP2017019776A5 JP2016131781A JP2016131781A JP2017019776A5 JP 2017019776 A5 JP2017019776 A5 JP 2017019776A5 JP 2016131781 A JP2016131781 A JP 2016131781A JP 2016131781 A JP2016131781 A JP 2016131781A JP 2017019776 A5 JP2017019776 A5 JP 2017019776A5
- Authority
- JP
- Japan
- Prior art keywords
- brain
- proband
- synucleopathy
- abcc1 transporter
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004556 brain Anatomy 0.000 claims 8
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 150000008134 glucuronides Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003688 hormone derivative Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000005070 sampling Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044561 | 2010-09-07 | ||
| DE102010044561.4 | 2010-09-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527544A Division JP6084924B2 (ja) | 2010-09-07 | 2011-08-30 | β−アミロイドパシーまたはα−シヌクレオパシーを治療するための２−（Ｒ２−チオ）−１０−［３−（４−Ｒ１−ピペラジン−１−イル）プロピル］−１０Ｈ−フェノチアジン、およびβ−アミロイドパシーまたはα−シヌクレオパシーの診断または事前診断のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017019776A JP2017019776A (ja) | 2017-01-26 |
| JP2017019776A5 true JP2017019776A5 (enExample) | 2017-03-23 |
| JP6426663B2 JP6426663B2 (ja) | 2018-11-21 |
Family
ID=44645670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527544A Active JP6084924B2 (ja) | 2010-09-07 | 2011-08-30 | β−アミロイドパシーまたはα−シヌクレオパシーを治療するための２−（Ｒ２−チオ）−１０−［３−（４−Ｒ１−ピペラジン−１−イル）プロピル］−１０Ｈ−フェノチアジン、およびβ−アミロイドパシーまたはα−シヌクレオパシーの診断または事前診断のための方法 |
| JP2016131781A Active JP6426663B2 (ja) | 2010-09-07 | 2016-07-01 | β−アミロイドパシーまたはα−シヌクレオパシーを治療するための２−（Ｒ２−チオ）−１０−［３−（４−Ｒ１−ピペラジン−１−イル）プロピル］−１０Ｈ−フェノチアジン、およびβ−アミロイドパシーまたはα−シヌクレオパシーの診断または事前診断のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527544A Active JP6084924B2 (ja) | 2010-09-07 | 2011-08-30 | β−アミロイドパシーまたはα−シヌクレオパシーを治療するための２−（Ｒ２−チオ）−１０−［３−（４−Ｒ１−ピペラジン−１−イル）プロピル］−１０Ｈ−フェノチアジン、およびβ−アミロイドパシーまたはα−シヌクレオパシーの診断または事前診断のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130184268A1 (enExample) |
| EP (3) | EP3097914A3 (enExample) |
| JP (2) | JP6084924B2 (enExample) |
| CN (2) | CN103237802B (enExample) |
| BR (1) | BR112013005472A2 (enExample) |
| CA (2) | CA2870626C (enExample) |
| DE (2) | DE102010062810B4 (enExample) |
| DK (2) | DK2693216T3 (enExample) |
| ES (2) | ES2605705T3 (enExample) |
| MX (1) | MX357521B (enExample) |
| PL (2) | PL2614060T3 (enExample) |
| RU (2) | RU2016118021A (enExample) |
| WO (1) | WO2012031941A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017301966B2 (en) | 2016-07-25 | 2022-09-22 | TauRx Therapeutics Management Ltd | Administration and dosage of diaminophenothiazines |
| EP3826639B1 (en) | 2018-07-26 | 2024-08-21 | WisTa Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
| EP4121546A1 (en) * | 2020-03-16 | 2023-01-25 | Doublerainbow Biosciences Inc. | Etoposide glycosides, methods of making, and uses thereof as an anti-cancer drug |
| EP4460311A1 (en) * | 2022-01-04 | 2024-11-13 | Immungenetics AG | Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia |
| CA3268498A1 (en) * | 2022-10-18 | 2024-04-25 | Immungenetics Ag | IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH365379A (de) * | 1956-04-18 | 1962-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen |
| BE568701A (enExample) * | 1957-06-18 | |||
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| US4471116A (en) * | 1982-07-28 | 1984-09-11 | Hoffmann-La Roche Inc. | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| DK1470818T3 (da) * | 2003-04-25 | 2006-11-20 | Neuro3D | Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| WO2007062862A2 (en) * | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| HUE030621T2 (en) * | 2006-07-11 | 2017-05-29 | Wista Lab Ltd | Methods for the synthesis and / or purification of diaminophenothiazinium compounds |
| ES2394377T3 (es) * | 2006-11-10 | 2013-01-31 | Cara Therapeutics, Inc. | Amidas de péptidos sintéticos |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2009133128A1 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| PT2282779E (pt) * | 2008-04-29 | 2013-05-28 | Pharnext | Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular |
| LT2282778T (lt) * | 2008-04-29 | 2017-06-26 | Pharnext | Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją |
| EP2429530B1 (en) * | 2009-05-14 | 2018-11-07 | The General Hospital Corporation | (s)-meclizine for treating ischaemia-reperfusion injury |
-
2010
- 2010-12-10 DE DE102010062810.7A patent/DE102010062810B4/de not_active Expired - Fee Related
-
2011
- 2011-08-30 ES ES11755294.3T patent/ES2605705T3/es active Active
- 2011-08-30 BR BR112013005472-7A patent/BR112013005472A2/pt not_active Application Discontinuation
- 2011-08-30 PL PL11755294T patent/PL2614060T3/pl unknown
- 2011-08-30 EP EP16180106.3A patent/EP3097914A3/de not_active Withdrawn
- 2011-08-30 DK DK13190419.5T patent/DK2693216T3/en active
- 2011-08-30 US US13/821,515 patent/US20130184268A1/en not_active Abandoned
- 2011-08-30 RU RU2016118021A patent/RU2016118021A/ru not_active Application Discontinuation
- 2011-08-30 EP EP13190419.5A patent/EP2693216B1/de active Active
- 2011-08-30 CA CA2870626A patent/CA2870626C/en active Active
- 2011-08-30 CN CN201180053670.4A patent/CN103237802B/zh active Active
- 2011-08-30 MX MX2013002612A patent/MX357521B/es active IP Right Grant
- 2011-08-30 ES ES13190419T patent/ES2701453T3/es active Active
- 2011-08-30 EP EP11755294.3A patent/EP2614060B1/de active Active
- 2011-08-30 DK DK11755294.3T patent/DK2614060T3/da active
- 2011-08-30 PL PL13190419T patent/PL2693216T3/pl unknown
- 2011-08-30 CA CA2811454A patent/CA2811454C/en active Active
- 2011-08-30 WO PCT/EP2011/064893 patent/WO2012031941A2/de not_active Ceased
- 2011-08-30 JP JP2013527544A patent/JP6084924B2/ja active Active
- 2011-08-30 RU RU2013110018/04A patent/RU2587154C2/ru active
- 2011-08-30 CN CN201610631393.5A patent/CN106243060A/zh active Pending
- 2011-08-30 DE DE102011053114A patent/DE102011053114A1/de not_active Ceased
-
2014
- 2014-09-29 US US14/499,918 patent/US9370523B2/en active Active
-
2015
- 2015-09-08 US US14/847,089 patent/US20150374711A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131781A patent/JP6426663B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017019776A5 (enExample) | ||
| French | Advances in clinical mass spectrometry | |
| Piton et al. | Plasma citrulline kinetics and prognostic value in critically ill patients | |
| Brendish et al. | Point-of-care testing for respiratory viruses in adults: the current landscape and future potential | |
| Michel et al. | Targeted metabolomic analysis of serum amino acids in the adult Fontan patient with a dominant left ventricle | |
| Bunevicius et al. | Ischemic stroke functional outcomes are independently associated with C-reactive protein concentrations and cognitive outcomes with triiodothyronine concentrations: a pilot study | |
| JP2010536012A (ja) | リスク階層化におけるプロカルシトニン（ｐｃｔ）の使用、及び原発性の非感染性疾患を有する患者の予後診断 | |
| Taggi et al. | Transporter regulation in critical protective barriers: focus on brain and placenta | |
| JP2013527437A5 (enExample) | ||
| WO2020234502A1 (es) | Procedimiento para el diagnostico y/o pronostico del sindrome de insuficiencia hepatica aguda sobre cronica en pacientes con trastornos hepaticos | |
| Kukla et al. | Irisin in liver cirrhosis | |
| Wickremsinhe et al. | Using dried blood spot sampling to improve data quality and reduce animal use in mouse pharmacokinetic studies | |
| Flieger et al. | Determination of tryptophan and its major metabolites in fluid from the anterior chamber of the eye in diabetic patients with cataract by liquid chromotography mass spectrometry (LC-MS/MS) | |
| Tonic-Ribarska et al. | Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in saliva | |
| Daeseleire et al. | Determination of flunixin and ketoprofen in milk by liquid chromatography–tandem mass spectrometry | |
| Chen et al. | Simultaneous assay of multiple antibiotics in human plasma by LC–MS/MS: importance of optimizing formic acid concentration | |
| González-Nicolás et al. | Biomarkers in contrast-induced acute kidney injury: towards a new perspective | |
| JP2024023615A (ja) | 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ | |
| Michels et al. | High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections | |
| Arayne et al. | Determination and quantification of cetirizine HCl in dosage formulations by RP-HPLC | |
| Vandenberghe et al. | Cerebrospinal fluid detection of enterovirus genome in ALS: a study of 242 patients and 354 controls | |
| Metcalfe et al. | An LC-MS/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair | |
| Remnitz et al. | Comparison of Methods of Detecting IL-1β in the Blood of Alzheimer’s Disease Subjects | |
| Caprioli et al. | Quantification of 17 endogenous and exogenous steroidal hormones in equine and bovine blood for doping control with UHPLC-MS/MS | |
| Tuma et al. | Development of an LC-HRMS/MS Method for Quantifying Steroids and Thyroid Hormones in Capillary Blood: A Potential Tool for Assessing Relative Energy Deficiency in Sport (RED-S) |